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Objective: The purpose of this study was to investigate the transport of inhibin A and to determine its effects
on fetal vascular pressure at elevated levels in the human placenta using
125I-labeled synthetic glycoprotein.
Methods: SyntheticinhibinAwaspreparedandwasshowntobeconsistentwiththenaturalformbyhigh-pressure
liquid chromatography (HPLC) and molecular weight determination by gas-chromatography mass spectrometry.
The standardized Na
125I process yielded
125I-labeled inhibin A with a radioactivity of 10
6 cpm/µg. This compound
was placed in the human placenta in maternal–fetal and fetal–maternal studies using antipyrine and
14C-labeled
inulin as controls to determine the bidirectional transfer of the compound.
Results: Maternal–fetal and fetal–maternal clearance indices were 0.045 ± 0.003 and 0, respectively. In eight
placentas there was no evidence of vascular pressure changes due to the presence of up to 5000 pg of inhibin A.
Conclusions: Thereisminimalmaternal–fetaltransferandnodetectablefetal–maternaltransferinnormotensive
and pregnancy-induced hypertensive placentas. In addition, there are no pressure changes in the fetal vascular
system due to the clinically significant levels of inhibin A.
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Inhibin is a dimeric, disulfide-linked glycoprotein
that is produced in the ovaries and the placenta,
and it is probably involved in the stimulation and
inhibition of cellular differentiation, proliferation
and morphogenesis. During gestation the placenta
is the main source of inhibin, the level of which
generally rises through gestation and peaks at
term. Inhibin consists of two subunits, namely the
A fragment and the B fragment. The A fragment
contains33aminoacidswithamolecularweightof
3796 daltons, and the inhibin B fragment has
27 amino acids with a molecular weight of 3300
daltons. Further studies indicate that there are at
least two forms of inhibin A, namely the biological
form and the immunological form, the latter form
being reactive in enzyme-linked immunosorbent
assays (ELISA) and the former only being respons-
ible for selectively inhibiting the secretion of
follicle-stimulating hormone (FSH)1–4. The level
of inhibin A (probably the immunological form)
has been shown to be elevated in patients diag-
nosed with pre-eclampsia. Previous studies have
shown that inhibin A levels become elevated as
early as 25 weeks’ gestation in pre-eclampsia and
gestational hypertension. These levels may exceed
a median level of 1833 pg/ml in severe cases5. The
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of inhibin A in normotensive and pre-eclamptic
placentas, and determined its effect on fetal vessel
pressure in the presence of elevated levels of
the glycoprotein.
MATERIALS AND METHODS
The ex-vivo human placental model was used in
this study, with modification according to
Challier6, Schneider et al.7 and Brandes et al.8. This
model has been used extensively to determine
the transfer and pressure effects of numerous
drugs, including some antiviral and antimicrobial
compounds9,10. These studies were approved by
the Institutional Review Board of our institution.
Eight placentas from Cesarean sections were
transported to the laboratory within 10 minutes
of delivery. The fetal artery and vein of a suit-
able cotyledon were cannulated with 3° and 5°
French catheters, respectively, to establish a
‘fetal circulation’. The maternal circulation was
established by insertion of two 18-guage blunt
needles about 1cm into the blanched intervillous
spaceoftheselectedcotyledon. Boththematernal
and fetal circulations were perfused with
heparinized drug-free Eagles minimum essential
medium containing 3% bovine serum albumin.
After approximately 30 minutes of perfusion, and
if no fetal–maternal leaks were detected, the
flow rates were set at 5.0 and 17.0 ml/minute,
respectively. The perfusates were maintained at
37°C with the system in a closed transparent
container. The pH was 7.35, and 95% O2 and
5% CO2 were bubbled into the perfusates to
maintain physiological pH and O2 concentra-
tion. Inhibin A was synthesized by a Ranin
Symphony Automated Peptide Synthesizer and
was provided by the Protein Technology Center
at the Howard Hughes Medical Institute, Univer-
sity of Texas Southwestern Medical Center.
Molecular weight determinations were done by
gas-chromatography (GC) mass spectrometry, and
purity was confirmed by high-pressure liquid
chromatography (HPLC). This was in order
to confirm that inhibin A was produced by this
methodology.
Iodination of inhibin A
Inhibin (100 µg) dissolved in 100 µl of 0.1mol/l
carbonate–bicarbonate buffer, pH 9.0, was radio-
labeled with 1mCi of Na 125I using the Iodogen
reagent (Amersham, Arlington Heights, IL)11,12.
The free iodine was removed by chromatography
on a microcolumn of Amberlite IRA-400 (Fluka,
Switzerland) equilibrated with the above-
mentioned buffer. The specific radioactivity of
the 125I-labeledinhibinAwasaround106 cpm/µg.
Samples from the maternal and fetal circulations
were collected every 10 minutes over a period of
several hours. One ml of sample was placed in a
12m m × 75 mm test tube, and 1.0 ml of 10%
trichloroacetic acid (TCA) was then added and the
sample was vortexed. The samples were centri-
fuged at 2000 rpm for 10 minutes to pellet the
precipitated radiolabeled inhibin and other pro-
tein; this allows the removal of free iodine. The
pellets were washed twice with 10% TCA and
counted on a gamma counter for 1minute
(Packard United Technologies Minaxi Auto-
Gama 5000 Series, Dowers Grove, IL).
Antipyrine
Approximately100 µg/mlofantipyrinewasadded
to the maternal circulation of each placenta.
Antipyrine concentrations were determined using
HPLC. In total, 0.5 ml of maternal or fetal
samples was extracted with 10% TCA for protein
and blood precipitation. The samples were centri-
fuged for 10 minutes at 2000 × g, and 20 µgo f
aqueous layer were injected into the HPLC
system. The HPLC conditions included a 486
detector, a 712 Waters Intelligent Sample Pro-
cessor, a C18 u-bond-a-pak column and a 10 mV
recorder (Waters Instruments, Milford, MA). The
detector sensitivity was 0.5 absorbance units at a
wavelength of 254 µm. The flow rate of the
25% acetonitrile in 0.01mol/l KPO 4 buffer,
pH 7.1, was 2.0 ml/minute.
Determination of 14C-labeled inulin
Inulin was added to the fetal circulation at a
concentration of 60 mg/l. 14C-labeled inulin was
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15.5 µCi/µg. 14C-labeled inulin was determined
by the addition of 0.10 ml of maternal or fetal
sample to a scintillation vial, then adding 5.0 ml
of counting cocktail and counting on a liquid
scintillation counter (Pharmacia Wallac Liquid
Scintillation Counter, Perkin Elmer Life Science
Corp., Boston, MA).
RESULTS
At 5000 pg/ml, the maternal–fetal clearance
index (CI) of 125I-labeled inhibin A was
0.045 ± 0.003,indicatinglittleornotransferofthe
labeled compound. The fetal–maternal CI of
125I-labeled inhibin A at concentrations of up to
5000 pg/ml was undetectable. Furthermore, the
maternal– fetal CI of the compound was 0.09 in
the two pregnancy-induced hypertensive placen-
tas, which was in the range of that for the four
normal placentas. There appears to have been no
change due to pregnancy-induced hypertension.
In addition, with these high levels of inhibin A
there was no change in the fetal vascular pressure
such as has been observed in previous placental
perfusion studies with antihypertensive drugs13.
DISCUSSION
In an effort to determine the movement of
inhibin A in the maternal–fetal compartment,
125I-labeledinhibinAwasusedatelevatedconcen-
trations not only to investigate this transfer but
also to determine the effects on the vascular
pressure in the fetal vessels. 125I-labeled inhibin A
was used not only to distinguish the compound
from the existence of endogenous inhibin A, but
also to allow an extremely sensitive radiolabeling
methodology to be used. It must be noted that
thesyntheticpeptideproducedbySigma(StLouis,
MO) and the peptide that was synthesized in our
laboratory did not react with the ELISA amplifica-
tion kit. Although the Sigma peptide did inhibit
the secretion of FSH in luteal cells, our peptide
was not tested. This finding may be due to the
addition of tyrosine, which is essential for binding
the peptide to 125I, thus perhaps changing the
receptor site used in the ELISA amplification kit.
However,itmayalsobeabiologicalratherthanan
immunological form of the peptide that reacts
in the ELISA method11,12,14.
Furthermore, with regard to the nonreactivity
with the ELISA amplification kit of our peptide
and that prepared by Sigma, both compounds
were identical as assessed by GC mass spectro-
metry, and the results of molecular weight deter-
minations and HPLC analyses were identical.
There may be an apparent difference between the
biological and immunological forms of inhibin A.
In addition, there are possible artifacts of the
radiolabeled inhibin that may interfere with the
ELISA-A assay2,3. Further studies indicate that
cord serum interferes with the measurement of
human inhibin A, due to the presence of inhibin-
binding proteins or proteolytic enzymes3,4.
As has been described in earlier publications,
inhibin A is not present as such in the fetal circula-
tion, and as our study demonstrates, it is not
transferredtothematernalcirculation.Inaddition,
maternal–fetal transfer is minimal in the ex-vivo
system, and is not related to an increase in vascular
pressure.
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